Bayer: Renal Insufficiency, Chronic trials

The registry lists 49 Renal Insufficiency, Chronic studies with Bayer as lead sponsor. 4 are open to participants now and 4 have results posted.

Phase 1 12Phase 2 10Phase 3 9Phase 4 1No phase 17(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn More About How Well Finerenone Works in Real-world in People With Type 2 Diabetes and Chronic Kidney Disease in Primary Care (IMSS= Instituto Mexicano Del Seguro Social)Not yet recruitingNCT07841015
• An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk ScoreRecruitingNCT07554469
• An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world ConditionsRecruitingNCT06278207
• A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaRecruitingNCT05457283Phase 3
• A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 DiabetesCompletedNCT05901831Phase 3Results posted
• A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 DiabetesCompletedNCT05254002Phase 2Results posted
• An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD ParticipantsCompletedNCT05013008Phase 2Results posted
• Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney DiseaseCompletedNCT02540993Phase 3Results posted
• A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Old Tablet and How Food Affects the Way the New Tablet is Absorbed and Processed in the BodyCompletedNCT07722585Phase 1
• A Study to Learn More About How Safe Nurandociguat is and How it Affects the Way the Body Processes Rosuvastatin and Dabigatran in Healthy AdultsWithdrawnNCT07515339Phase 1
• An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South KoreaActive, not recruitingNCT07232537
• An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.CompletedNCT07124039
• An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical PracticeActive, not recruitingNCT06763146
• An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United StatesCompletedNCT06608212
• A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney DiseaseCompletedNCT06522997Phase 2
• A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese ParticipantsCompletedNCT06487845Phase 1
• A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood PressureCompletedNCT06428825Phase 1
• A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver FunctionCompletedNCT06402721Phase 1
• An Observational Study to Learn More How Chronic Kidney Disease Gradually Changes Over Time in Adults Using Electronic Healthcare Records (CKD Natural History Study)CompletedNCT05914259
• A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male ParticipantsCompletedNCT05800444Phase 1
• A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes MellitusCompletedNCT05705271Phase 4
• An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world ConditionsCompletedNCT05703880
• An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study ResultsCompletedNCT05640180
• A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus PatientsCompletedNCT05552339
• An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical PracticeCompletedNCT05526157
• A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and WeightCompletedNCT05515432Phase 1
• A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple DosesCompletedNCT05491642Phase 1
• A Study Using Surveys to Learn More About Treatment With Steroidal Mineralocorticoid Receptor Antagonists, How They Are Used, What Side Effects They Have, and How Satisfied People Who Receive Them Are in the USCompletedNCT05407662
• A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care SettingActive, not recruitingNCT05348733
• A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and ProteinuriaActive, not recruitingNCT05196035Phase 3
• A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)CompletedNCT05004428
• A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender DistributionCompletedNCT04908436Phase 1
• Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver ImpairmentTerminatedNCT04820621Phase 1
• A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.WithdrawnNCT04661917Phase 2
• Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.CompletedNCT04507061Phase 2
• Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)CompletedNCT04498156
• Maintenance Treatment of Renal Anemia in Dialysis SubjectsCompletedNCT03543657Phase 3
• A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis SubjectsCompletedNCT03418168Phase 3
• A Study of Molidustat for Correction of Renal Anemia in Dialysis SubjectsCompletedNCT03351166Phase 3
• A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis SubjectsCompletedNCT03350347Phase 3
• A Study of Molidustat for Correction of Renal Anemia in Non-dialysis SubjectsCompletedNCT03350321Phase 3
• Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male SubjectsCompletedNCT03252002Phase 1
• To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy SubjectsCompletedNCT02312973Phase 1
• Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934CompletedNCT02064426Phase 2
• Long-term Pre-dialysis Extension in Europe and Asia PacificCompletedNCT02055482Phase 2
• Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934CompletedNCT02021409Phase 2
• 15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)CompletedNCT02021370Phase 2
• Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934CompletedNCT01975818Phase 2
• Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney DiseaseCompletedNCT01363336